Nav: Home

Subgroup of colorectal cancer patients ID'd: Do poorly, could benefit from immunotherapy

September 16, 2019

DUARTE, Calif. -- While the medical community agrees that immune cells inside a tumor leads to improved health outcome, for a subset of colorectal cancer patients, having too much of a good thing - too many immune cells - is a strong predictor of disease recurrence and reduced chances of survival, according to new research from City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases.

"Having immune cells in tumors is widely recognized as a good thing, but we found that too much of a good thing is actually bad," said Peter P. Lee, M.D., chair of the Department of Immuno-Oncology at City of Hope and senior author of a study published in the Journal of Clinical Investigation on Sept. 16.

The researchers examined colorectal cancer, the third-leading cause of cancer-related deaths in the United States.

"This study is the first report of immune infiltrated tumors with poor health outcomes and is counter to the standard belief in the field," said Lee, the Billy and Audrey L. Wilder Professor in Cancer Immunotherapeutics. "This is a new way to look at colorectal tumors and is a reminder that physicians cannot base treatment merely on established, one-size-fits all treatment templates."

City of Hope physician-scientists are working on precision medicine research so that their patients can receive more bespoke treatment. They analyzed public genomic data sets from The Cancer Genome Atlas and NCBI Gene Expression Omnibus and validated their findings with data from 71 City of Hope patients diagnosed with Stage 3 colorectal cancer.

About 10% of these City of Hope colorectal cancer patients had a cornucopia of immune cells turned on, including CD8+ T cells. However, this group of patients all relapsed. In fact, they relapsed even earlier than patients with little or no immune cells in their tumors. The problem appeared to be that their immune system was on overdrive; they also had their immune checkpoint inhibitors - the proteins that put the immune system in neutral - in overdrive. The result is like two trains colliding: No one going anywhere fast.

Based on a series of analyses and cross-validation tests, the researchers were able to stratify the patients into four categories. Patients with high levels of immune cell infiltration and high levels of the checkpoint inhibitor PD-L1 were two to three times more likely to die from colorectal cancer compared to their peers who had tons of immune cell infiltration and low levels of checkpoint inhibitors.

Although the study needs to be duplicated in a prospective study with a larger sample size, the researchers propose that PD-L1 expression and CD8 combined score could be used as a biomarker to identify colorectal cancer patients who may require more aggressive monitoring and treatment.

"Patients in this subgroup may be good candidates for immunotherapy to reduce the chances of disease recurrence," said Marwan Fakih, M.D., co-director of the Gastrointestinal Cancer Program at City of Hope and lead author of the study.

About 60% of the patients in this subgroup had tumors that are "microsatellite instable," a disease category that points to people who typically have had positive responses to an immunotherapy that uses immune checkpoint inhibitors.

"Those in this subgroup who have high immune cell infiltration and a high immune-suppressive tumor microenvironment should be considered for enrollment in clinical trials that use immune checkpoint inhibitors," Fakih said. "If we continue to treat these patients with standard of care, they will continue to have a poor prognosis. We should use what we learned in this study to improve their chances of survival."

The study provides a more nuanced understanding of Immunoscore, a recent benchmark used to predict risk of colorectal cancer recurrence. Most colorectal patients who have tumors with high CD8+ T-cell infiltration still have favorable outcomes. However, City of Hope researchers found that if those patients also have high levels of PD-L1 expression, they may be mislabeled as having a good prognosis by Immunoscore, which relies solely on expression of CD3 and CD8 immune T cells.

City of Hope scientists are beginning to apply the same techniques used in this study to examine data on breast cancer patients. They plan to use the same process to analyze other cancers such as melanoma and lung cancer.
-end-
The study used material that was funded by the National Cancer Institution and the National Institutes of Health.

About City of Hope

City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hope's translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin and numerous breakthrough cancer drugs are based on technology developed at the institution. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is the highest ranked cancer hospital in the West, according to U.S. News & World Report's Best

City of Hope

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Teaching For Better Humans 2.0
More than test scores or good grades–what do kids need for the future? This hour, TED speakers explore how to help children grow into better humans, both during and after this time of crisis. Guests include educators Richard Culatta and Liz Kleinrock, psychologist Thomas Curran, and writer Jacqueline Woodson.
Now Playing: Science for the People

#556 The Power of Friendship
It's 2020 and times are tough. Maybe some of us are learning about social distancing the hard way. Maybe we just are all a little anxious. No matter what, we could probably use a friend. But what is a friend, exactly? And why do we need them so much? This week host Bethany Brookshire speaks with Lydia Denworth, author of the new book "Friendship: The Evolution, Biology, and Extraordinary Power of Life's Fundamental Bond". This episode is hosted by Bethany Brookshire, science writer from Science News.
Now Playing: Radiolab

Space
One of the most consistent questions we get at the show is from parents who want to know which episodes are kid-friendly and which aren't. So today, we're releasing a separate feed, Radiolab for Kids. To kick it off, we're rerunning an all-time favorite episode: Space. In the 60's, space exploration was an American obsession. This hour, we chart the path from romance to increasing cynicism. We begin with Ann Druyan, widow of Carl Sagan, with a story about the Voyager expedition, true love, and a golden record that travels through space. And astrophysicist Neil de Grasse Tyson explains the Coepernican Principle, and just how insignificant we are. Support Radiolab today at Radiolab.org/donate.